Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Enterprise Value (2016 - 2026)

United Therapeutics' Enterprise Value history spans 17 years, with the latest figure at -$2.9 billion for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 10.61% to -$2.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.9 billion, a 10.61% increase, with the full-year FY2025 number at -$2.9 billion, up 10.61% from a year prior.
  • Enterprise Value hit -$2.9 billion in Q4 2025 for United Therapeutics, down from -$2.8 billion in the prior quarter.
  • Over the last five years, Enterprise Value for UTHR hit a ceiling of -$1.7 billion in Q1 2021 and a floor of -$3.3 billion in Q3 2024.
  • Historically, Enterprise Value has averaged -$2.7 billion across 5 years, with a median of -$2.8 billion in 2022.
  • Biggest five-year swings in Enterprise Value: tumbled 47.03% in 2022 and later grew 16.8% in 2025.
  • Tracing UTHR's Enterprise Value over 5 years: stood at -$1.9 billion in 2021, then crashed by 47.03% to -$2.8 billion in 2022, then decreased by 5.47% to -$3.0 billion in 2023, then fell by 9.11% to -$3.3 billion in 2024, then increased by 10.61% to -$2.9 billion in 2025.
  • Business Quant data shows Enterprise Value for UTHR at -$2.9 billion in Q4 2025, -$2.8 billion in Q3 2025, and -$3.0 billion in Q2 2025.